Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinfl… Read more
Alumis Inc (ALMS) - Total Assets
Latest total assets as of September 2025: $488.01 Million USD
Based on the latest financial reports, Alumis Inc (ALMS) holds total assets worth $488.01 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alumis Inc - Total Assets Trend (2022–2024)
This chart illustrates how Alumis Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alumis Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Alumis Inc's total assets of $488.01 Million consist of 89.8% current assets and 10.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.7% |
| Accounts Receivable | $1.81 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Alumis Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alumis Inc's current assets represent 89.8% of total assets in 2024, a decrease from 94.8% in 2022.
- Cash Position: Cash and equivalents constituted 49.7% of total assets in 2024, up from 23.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Alumis Inc Competitors by Total Assets
Key competitors of Alumis Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Alumis Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Alumis Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Alumis Inc is currently not profitable relative to its asset base.
Alumis Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.01 | 11.26 | 2.56 |
| Quick Ratio | 6.01 | 11.26 | 2.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $327.87 Million | $ 343.83 Million | $ 32.49 Million |
Alumis Inc - Advanced Valuation Insights
This section examines the relationship between Alumis Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.71 |
| Latest Market Cap to Assets Ratio | 5.09 |
| Asset Growth Rate (YoY) | 280.5% |
| Total Assets | $340.99 Million |
| Market Capitalization | $1.74 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Alumis Inc's assets at a significant premium ( 5.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alumis Inc's assets grew by 280.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alumis Inc (2022–2024)
The table below shows the annual total assets of Alumis Inc from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $340.99 Million | +280.52% |
| 2023-12-31 | $89.61 Million | -17.15% |
| 2022-12-31 | $108.17 Million | -- |